Jean Jacques Bienaime - 10 Mar 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
10 Mar 2022
Net transactions value
-$1,206,900
Form type
4
Filing time
14 Mar 2022, 20:44:52 UTC
Previous filing
10 Mar 2022
Next filing
17 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $561,900 +15,000 +4.4% $37.46 353,569 10 Mar 2022 Direct F1
transaction BMRN Common Stock Sale $1,163,550 -15,000 -4.2% $77.57 338,569 10 Mar 2022 Direct F1
transaction BMRN Common Stock Options Exercise $561,900 +15,000 +4.4% $37.46 353,569 11 Mar 2022 Direct F1
transaction BMRN Common Stock Sale $1,167,150 -15,000 -4.2% $77.81 338,569 11 Mar 2022 Direct F1
holding BMRN Common Stock 247,533 10 Mar 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -15,000 -13% $0.000000 100,000 10 Mar 2022 Common Stock 15,000 $37.46 Direct F1, F2
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -15,000 -15% $0.000000 85,000 11 Mar 2022 Common Stock 15,000 $37.46 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.